[Problems of cumulative toxicity of radiotherapy and cytostatic chemotherapy in bronchial carcinoma].
The possible toxicities of combined modality therapy in bronchogenic carcinoma are reviewed. Enhancement of local and systemic side effects of each treatment form are the main risks to reduce quality of survival in these patients. Recent studies did not yet resolve the problems of optimal chemotherapy, dose of radiation necessary to obtain complete responses more frequently, or timing of the administration of chemotherapy and radiotherapy. Until significant survival benefits due to combined modality treatment are proven in patients with bronchogenic carcinoma, combined therapy should be given in controlled clinical trials only.
D000818:Animals; D000970:Antineoplastic Agents / Q000009:adverse effects* / Q000627:therapeutic use; D002283:Carcinoma, Bronchogenic / Q000628:therapy; D004359:Drug Therapy, Combination; D006801:Humans; D008175:Lung Neoplasms / Q000628:therapy*; D011832:Radiation Injuries / Q000209:etiology; D011878:Radiotherapy / Q000009:adverse effects*; D011879:Radiotherapy Dosage
D000970:Antineoplastic Agents
Probleme der kumulativen Toxizität von Radiotherapie und zytostatischer Chemotherapie beim Bronchialkarzinom.